Silvia Bertolone
Artificial Intelligence and Drug Discovery: Exploring the effects on competencies, resources, and management in pharmaceutical companies.
Rel. Marco Cantamessa, Sebastian Bouschery. Politecnico di Torino, Corso di laurea magistrale in Ingegneria Gestionale, 2023
Abstract
Artificial intelligence (AI) is one of the most relevant and controversial technologies of the 21st century. AI and its subcategories, machine learning (ML) and deep learning (DL), are wide-ranging tools supporting humans during decisional processes. The widespread use of computational methods is a phenomenon observed across almost every sector, from the most traditional to digital and the pharmaceutical industry. For the latter, this has been particularly the case since the Covid-19 crisis. The critical activity of each pharma company is called drug discovery and development (DDD): it is a process that, according to literature, takes an average of 10,5 years (Thomas et al., 2021, p.
24), costing billions of dollars, and with a significant risk of failure
Relatori
Anno Accademico
Tipo di pubblicazione
Numero di pagine
Informazioni aggiuntive
Corso di laurea
Classe di laurea
Ente in cotutela
Aziende collaboratrici
URI
![]() |
Modifica (riservato agli operatori) |
